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Satellite cells are skeletal muscle stem cells that provide myo-
nuclei for postnatal muscle growth, maintenance, and repair/
regeneration in adults. Normally, satellite cells are mitotically
quiescent, but they are activated in response to muscle injury, in
which case they proliferate extensively and exhibit up-regulated
expression of the transcription factor MyoD, a master regulator
of myogenesis. MyoD forms a heterodimer with E proteins
through their basic helix-loop-helix domain, binds to E boxes in
the genome and thereby activates transcription at muscle-spe-
cific promoters. The central role of MyoD in muscle differenti-
ation has increased interest in finding potential MyoD regula-
tors. Here we identified transducin-like enhancer of split
(TLE3), one of the Groucho/TLE family members, as a regulator
of MyoD function during myogenesis. TLE3 was expressed in
activated and proliferative satellite cells in which increased
TLE3 levels suppressed myogenic differentiation, and, con-
versely, reduced TLE3 levels promoted myogenesis with a con-
comitant increase in proliferation. We found that, via its gluta-
mine- and serine/proline-rich domains, TLE3 interferes with
MyoD function by disrupting the association between the basic
helix-loop-helix domain of MyoD and E proteins. Our findings
indicate that TLE3 participates in skeletal muscle homeostasis
by dampening satellite cell differentiation via repression of
MyoD transcriptional activity.
Skeletal muscle consists of postmitotic multinucleated myo-
fibers that are derived from skeletal muscle stem cells called
satellite cells that reside beneath the basal lamina. Satellite cells
are normally mitotically quiescent but are activated in response
to stimulation, such as muscle injury, to become myoblasts and
proliferate extensively (1, 2). Quiescent satellite cells express
Pax7 in adult muscle and, upon stimulation, up-regulate
expression of the master regulator of myogenesis MyoD (3–5).
MyoD forms a heterodimer with E proteins, such as E12 and
E47, through their basic helix-loop-helix (bHLH)2 domain
and can bind E box genomic sequences, comprised of the
nucleotides CANNTG, as heterodimers with E proteins and
activate transcription at muscle-specific promoters (6).
Along with three related proteins, Myf5 (7), Myogenin (8),
and MRF4 (also known as Myf6 or herculin) (9 –11), MyoD
constitutes a family of transcription factors called myogenic
regulatory factors (MRFs). MRFs display a certain degree of
functional redundancy (12, 13) and share a highly conserved
variant of the bHLH domain that confers their myogenic
potential (14).
Groucho/TLE family members are transcriptional co-factors
that do not bind DNA directly but play critical roles during
development and cell differentiation events (15). Groucho/TLE
proteins consist of a five-domain structure (16): a highly con-
served Q domain, which is a glutamine-rich region predicted to
form two coiled-coil motifs that facilitates oligomerization
of Gro/TLE molecules (17–19); a glycine/proline-rich (GP)
domain, which is essential for interaction of Groucho/TLE
proteins with histone deacetylases (18, 20, 21); a CcN
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domain, which contains a nuclear localization sequence and
putative cdc2 and casein kinase II (CK2) phosphorylation
sites; a serine/proline-rich (SP) domain, which is a region
rich in serine/proline residues (16, 22–24); and a highly con-
served WD40 domain, which contains multiple tryptophan
and aspartic acid tandem repeats, has been shown by X-ray
crystallography to form a  propeller, and binds many kinds
of transcriptional factors (15, 25).
The Groucho/TLE family member TLE3 is expressed in white
adipose tissue. Recently, Villanueva et al. (26, 27) reported that
TLE3 enhanced the transcriptional activity of PPAR (peroxi-
some proliferator-activated receptor ) and induced adipogenesis
in preadipocytes. We have also reported that TLE3 induces adipo-
genesis and suppresses osteoblastogenesis in bone marrow–
derived mesenchymal stem cells (28, 29). Even though TLE3 is
expressed in embryonic somites and somite-derived myoblasts
with an expression pattern overlapping that of MyoD and Myf5
(30), the function of TLE3 in skeletal muscle tissue is still
unknown. Thus, we sought to examine the possibility that TLE3
regulates myogenesis and found that TLE3 represses myogenic
differentiation through a suppressive effect on MyoD activity.
Results
TLE3 is up-regulated in activated satellite cells of skeletal
muscle
We took advantage of an ex vivo model wherein myofibers
and associated satellite cells are isolated from the extensor digi-
torum longus (EDL) muscle of mice to characterize the expres-
sion of TLE3 during myogenesis. TLE3 protein was nearly
undetectable in Pax7-positive, quiescent satellite cells on
freshly isolated myofibers (day 0) (Fig. 1A). However, after cul-
turing in mitogen-rich medium for 2 days, TLE3 was expressed
in Pax7-positive and MyoD-positive satellite cells (Fig. 1A).
TLE3 protein was observed in Ki67-positive proliferative satel-
lite cells (Fig. 1, A and B). These findings suggest that TLE3
expression correlates with myogenic status.
To extend these findings to the in vivo setting, we utilized
cardiotoxin (CTX) to stimulate activation of satellite cells in
vivo and found that the expression levels of TLE3 mRNA and
protein in muscle were increased after CTX injection (Fig. 1, C
and F). This expression occurred prior to the up-regulation of
Cyclin A2, a proliferation maker (Fig. 1, D and F). In contrast,
Figure 1. TLE3 is expressed in activated and proliferating satellite cells of skeletal muscles. A, isolated EDL myofibers with their associated satellite cells
were either immediately fixed (Day 0) or cultured in plating medium for 2 days before fixation and immunostaining for TLE3, Pax7, MyoD, or Ki67. Arrowheads
indicate satellite cells. B, immunocytochemistry on satellite cells plated on Matrigel confirmed that TLE3 was expressed in activated and Ki67-positive prolif-
erating satellite cells maintained in growth medium (GM) for 7 days (7d) after isolation. C–F, mice were sacrificed 0 (Intact), 1, 3, 5, 7, 10, or 14 days after CTX
injection. Gene expression of TLE3 (C), Cyclin A2 (D), and Myogenin (E) was analyzed by qPCR. Protein levels of TLE3, Myogenin, Cyclin A2, and -actin were
assessed by Western blotting (F). G, mice were sacrificed 3.5 days after CTX injection (CTX 3.5d) and tibial anterior muscle cryosections were analyzed by
immunostaining for Pax7, MyoD, and TLE3. The data in A, B, F, and G are representative of at least three individual mice. Scale bars  20 m (A and G) and 40 m
(B). The data in C–E are expressed as the mean  S.D. (n  3). **, p  0.01 versus intact.
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the expression of Myogenin, a differentiation maker, was
increased, followed by down-regulation of TLE3 (Fig. 1, E and
F). Immunohistochemistry confirmed that all activated satellite
cells expressed TLE3 in vivo (Fig. 1G). These data suggest that
the expression of TLE3 protein links cell proliferation and/or
cell differentiation of satellite cells.
TLE3 stimulates cell proliferation and suppresses cell
differentiation in primary satellite cells
To examine the function of TLE3, endogenous TLE3 was
knocked down by shRNA or siRNA in satellite cells (Fig. 2, A
and G). Reduced TLE3 levels were associated with diminished
levels of the proliferation makers Cyclin D1 and Cyclin A2 (Fig.
2, B, C, H, I, L, and M), and knockdown of TLE3 stimulated cell
proliferation of plated satellite cells (Fig. 2O). In contrast, the
mRNA levels of myogenic differentiation maker genes such as
Myogenin, muscle creatine kinase (MCK), and myosin heavy
chain 14 (Myh14) were increased in shTLE3- or siTLE3-trans-
fected satellite cells under myogenic conditions (Fig. 2, D–F,
J–L, and N), suggesting that TLE3 stimulates proliferation and
inhibits myogenic differentiation of primary satellite cells.
TLE3 suppresses myogenic differentiation in C2C12 cells
To examine the mechanism(s) by which TLE3 regulates
myogenic differentiation of satellite cells, we turned to the
C2C12 cell model because these cells are satellite cell– derived
(31) and express TLE3 in their nuclei (Fig. 3A). Under myogenic
conditions, reducing TLE3 expression with shRNA against
TLE3 in C2C12 cells increased the protein level of Myogenin
and MHC (Fig. 3B and supplemental Fig. 1A) and promoted
myoblast fusion (Fig. 3, C and D). This repressive effect of TLE3
shRNA on myogenic differentiation was confirmed by intro-
duction of siRNA against TLE3 into cells (Fig. 3, E–H).
Knockdown of endogenous TLE3 did not, however, affect
the expression levels of MyoD, a master regulator of myo-
genic differentiation (Fig. 3B).
TLE3 interacts with MyoD and represses MyoD transcriptional
activity
We next hypothesized that TLE3 regulates the activity of
MyoD. Co-immunoprecipitation revealed that TLE3 interacts
with MyoD endogenously in C2C12 cells (Fig. 4A). To further
understand these findings, we turned to the C3H10T1/2 cell
Figure 2. Knockdown of TLE3 expression stimulates myoblast differentiation and reduces proliferation of plated satellite cells. A–F, plated satellite
cells were transfected with control shRNAs (Mock) or shRNAs against TLE3 (shTLE3) and then cultured in either growth medium (GM) (A–C) or differentiation
medium (DM) (D–F) for 2 days, and gene expression was analyzed by qPCR. Myog, Myogenin. G–K, plated satellite cells were transfected with control siRNAs
(Mock) or siRNA against TLE3 (siTLE3) and then cultured in GM (G–I) or DM (J and K) for 2 days, and gene expression was analyzed by qPCR. L–O, plated satellite
cells were transfected with control siRNA (Mock) or siRNA against TLE3 (siTLE3) and cultured in GM for 2 days (L, M, and O) or DM for 3.5 days (L and N) after
transfection. Immunocytochemistry analysis was performed using anti-TLE3, anti-Cyclin D1, or anti-MHC antibodies. Scale bars  100 m (L). M and N, protein
levels of Cylin D1, Cyclin A2, MHC, TLE3, and -actin were assessed by Western blotting. Proliferation of plated satellite cells following TLE3 knockdown was
assessed using Cell Counting Kit 8 (O). Similar results were obtained in three independent experiments (L and M). The data are expressed as mean  S.D. (n 
3). **, p  0.01; *, p  0.05 versus control shRNAs (Mock) or siRNA-transfected cells (A–K and O).
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model, which has myogenic potential but no expression of
MyoD as well as low TLE3 expression levels compared with
C2C12 cells (supplemental Fig. 2). Consistent with our prior
results (Fig. 4A), physical interaction was observed between
epitope-tagged versions of TLE3 and MyoD in C3H10T1/2
cells (Fig. 4B). Furthermore, overexpression of MyoD led to
increased expression of Myogenin, MCK, and Myh14, which
was then blunted by overexpression of TLE3 (Fig. 4, C–E). TLE3
also reduced the protein levels of Myogenin and MHC as well as
the number of MHC-positive cells induced by MyoD (Fig. 4,
F–H, and supplemental Fig. 1B). We employed luciferase
reporters driven by MG185 and MCK0.8 promoters to con-
firm that this effect was due to TLE3 repressing MyoD-de-
pendent transcriptional activity (Fig. 4, I and J). TLE3 also
repressed the transcriptional activity of other MRFs such as
Myf5, Myogenin, and MRF4 (supplemental Fig. 3). Further-
more, ChIP assays revealed that overexpression of TLE3 sup-
pressed the binding capacity of MyoD to the myogenin pro-
moter region (Fig. 4K).
Both the Q and SP domains of TLE3 are essential for MyoD
interaction and repression
Truncation mutants of TLE3 were designed to examine the
domain(s) of TLE3 involved in the interaction with and inhibi-
tion of MyoD (Fig. 5A). Prior studies indicate that the WD
domain of Groucho/TLE plays a critical role in regulating tran-
scription (32). However, the WD domain deletion mutant of
TLE3 (1– 461) still repressed MyoD transcriptional activity, as
assessed by MG185-luciferase assay (Fig. 5B). Consistent with
this, both full-length TLE3 (1–782) and WD domain deletion
mutant TLE3 (1– 461) physically interacted with MyoD (Fig.
5C). We also confirmed that, unlike full-length TLE3, the WD
domain deletion TLE3 (1– 461) failed to repress the transcrip-
tional activity of a known TLE3 target, Runx2 (28) (supplemen-
tal Fig. 4).
Having demonstrated that the WD domain is not necessary
for interacting with MyoD, we generated additional deletion
mutants of TLE3 and examined their ability to affect MyoD
activity. This revealed that mutants lacking the SP domain in
TLE3 (1–278) did not block MyoD activity, nor did they show
physical interaction with MyoD (Fig. 5, B and C). An additional
series of N-terminal mutants (Fig. 5D) demonstrated that
mutants lacking the Q domain in TLE3 (141–782), TLE3 (209 –
782), and TLE3 (279 –782) did not interact with MyoD (Fig. 5E)
or repress the transcriptional activity of MyoD (Fig. 5F). Col-
lectively, our results indicate that both the Q and SP domains of
TLE3 are essential for interacting with and repressing MyoD.
Figure 3. TLE3 regulates myoblast differentiation in C2C12 cells. A, C2C12 myoblasts were immunostained with anti-TLE3 antibody or normal IgG
together with phalloidin and DAPI. Scale bar  20 m. B–D, C2C12 cells were transfected with control shRNA (Mock) or shRNA against TLE3 (shTLE3) and
then cultured in myogenic medium. Western blot analysis with anti-TLE3 antibody showed reduction of endogenous TLE3 by shTLE3 along with
increased Myogenin on day 2 (B). C and D, C2C12 cells transfected with control (Mock) or shRNA against TLE3 (shTLE3) were cultured in myogenic
medium for 5 days and immunostained with anti-MHC antibody. Scale bar  50 m (C). The number of MHC-positive fibers (Fusion Index) was quantified
on day 5 (D). E–G, cells were transfected with control siRNA (Mock) or siRNA against TLE3 (siTLE3) and cultured in myogenic medium. The mRNA levels
of TLE3 (E), Myogenin (F), and Myh14 (G) were assessed by qPCR analysis on day 2. H, the protein levels of MHC, TLE3, Myogenin, and -actin were
assessed by Western blotting analysis on day 3. Similar results were obtained in three independent experiments (A–C and H). The data are expressed as
mean  S.D. (n  3). **, p  0.01 versus mock-transfected cells (D and E–G).
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The suppressive mechanism of TLE3 on MyoD involves
an E protein
We next generated two deletion mutants of MyoD to deter-
mine which domains of MyoD were targeted by TLE3 (Fig. 6A).
Although MyoD (1–99) failed to induce MG185-luc activity,
presumably because this mutant lacked the bHLH domain (14),
full-length MyoD (1–318) and C-terminal transactivation
domain deletion MyoD (1–167) were able to induce MG185-
luc activity. TLE3 firmly repressed these activities (Fig. 6B),
indicating that the C-terminal transactivation domain is not
required for interaction with TLE3. Subsequent immunopre-
cipitation assays revealed that only the bHLH domain of MyoD
is required to interact with TLE3 (Fig. 6C).
Finally, given that the MyoD also interacts with E proteins
such as E12 through its bHLH domain (33), we predicted that
TLE3 competes with E12 for binding to MyoD. Overexpression
of E12 alone only slightly increased MG185-luc activity (sup-
plemental Fig. 5), whereas co-expression of E12 with MyoD
significantly enhanced luciferase activity induced by MyoD
(Fig. 7A). Overexpression of E12 rescued the suppressive effect
of TLE3 on MyoD activity in a dose-dependent manner (Fig.
7A). TLE3 did not interact with E12 (Fig. 7B), but overexpres-
Figure 4. TLE3 suppresses myoblast differentiation in C3H10T1/2 cells. A, whole-cell lysates from C2C12 cells were immunoprecipitated (IP) using anti-
MyoD antibody and immunoblotted (IB) with an anti-TLE3 antibody. C3H10T1/2 cells were co-transfected with FLAG-tagged MyoD and either a mock vector
or Myc-tagged TLE3. B, whole-cell lysates were immunoprecipitated using FLAG-tagged magnetic agarose beads and immunoblotted with anti-Myc or
anti-FLAG. C–H, C3H10T1/2 cells were co-transfected with empty vector (Mock) or TLE3 along with MyoD. The mRNA levels of Myogenin (C), MCK (D), or Myh14
(E) were determined by qPCR on day 2. Western blot analysis was performed using anti-Myogenin antibody, anti-FLAG-antibody, anti-Myc-antibody, and
anti--actin antibody on day 2 (F). G and H, immunocytochemical analysis was performed using anti-MHC antibody. Scale bar  50 m (G), and MHC-positive
cells were counted on day 3 (H). I and J, C3H10T1/2 cells were transfected with TLE3 or empty vector (Mock) along with MyoD and MG185-luc (I) or MCK0.8-luc
(J) reporter plasmid. Cells were transfected with FLAG-tagged MyoD together with or without Myc-tagged TLE3. K, chromatin immunoprecipitation analysis
with anti-FLAG antibody and PCR primers for the Myogenin promoter. Similar results were obtained in three independent experiments (A, B, F, G, and K). The
data are expressed as mean  S.D. (n  3). **, p  0.01; *, p  0.05 versus mock-transfected cells (C–E, H, I, and J).
TLE3 represses MyoD transactivation
























Figure 5. Both the Q and SP domain of TLE3 are essential for MyoD interaction and repression. A, schematic of the C-terminally truncated forms of the
Myc-tagged TLE3 constructs used in these experiments. GP, glycine/proline-rich domain. B, C-terminally truncated forms of TLE3 or empty vector (Mock) were
co-transfected with the MG185-luciferase reporter along with MyoD in C3H10T1/2 cells. Luciferase activity was determined on day 1. C3H10T1/2 cells were
co-transfected with the FLAG-tagged MyoD and empty vector (Mock) or C-terminally truncated forms of Myc-tagged TLE3. C, whole-cell lysates were immu-
noprecipitated (IP) using anti-FLAG magnetic beads and immunoblotted (IB) with an anti-Myc antibody or anti-FLAG antibody. D, schematic of the N-terminally
truncated forms of the Myc-tagged TLE3 constructs. C3H10T1/2 cells were co-transfected with the FLAG-tagged MyoD and empty vector (Mock) or N-termi-
nally truncated forms of Myc-tagged TLE3. E, whole-cell lysates were immunoprecipitated using FLAG-tagged magnetic agarose and immunoblotted with an
anti-Myc antibody or anti-FLAG antibody. Empty vector (Mock) or N-terminally truncated forms of TLE3 were transfected with MG185-luciferase reporter along
with MyoD in C3H10T1/2 cells. F, luciferase activity was determined on day 1. Similar results were obtained in three independent experiments (C and E). The
data are expressed as mean  S.D. (n  3). **, p  0.01 versus mock-transfected cells (B and F).
Figure 6. TLE3 interacts with the bHLH domain of MyoD. A, schematic of the C-terminally truncated forms of the Myc-tagged MyoD constructs used in these
experiments. N-TAD, N-terminal transactivation domain; C-TAD; C-terminal transactivation domain. B, Empty vector (Mock) or C-terminally truncated forms of
MyoD were transfected with MG185-luciferase reporter with or without TLE3 in C3H10T1/2 cells. Luciferase activity was determined on day 1. The data are
expressed as mean  S.D. (n  3). **, p  0.01 versus mock-transfected cells. C3H10T1/2 cells were co-transfected with the FLAG-tagged TLE3 and empty vector
(Mock) or C-terminally truncated forms of Myc-tagged MyoD. C, whole-cell lysates were immunoprecipitated (IP) using anti-FLAG magnetic beads and
immunoblotted (IB) with an anti-Myc antibody or anti-FLAG antibody. Similar results were obtained in three independent experiments.
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sion of TLE3 decreased the interaction between E12 and MyoD
(Fig. 7C). This suggests that TLE3 interacts with MyoD and
masks the E protein-binding region on MyoD, and thus TLE3
competitively interferes with MyoD interactions. In addition,
although Mef2 also interacts with MyoD and enhances the
transcriptional activity of MyoD (34), TLE3 did not inhibit the
transcriptional synergy between MyoD and Mef2 (supplemen-
tal Fig. 6).
Discussion
In this study, we report that TLE3 represses MyoD activity,
and, thus, myogenic differentiation, by a mechanism that
involves, at least in part, disruption of MyoD and E protein
association (Fig. 7D). Furthermore, the expression of TLE3
appears to be related to the proliferative status of the cell (Figs.
1 and 2), suggesting that TLE3 may orchestrate satellite cell
proliferation and differentiation during myogenesis. However,
TLE3 expression is not completely absent in Myogenin-positive
cells (supplemental Fig. 7), and overexpression of TLE3 exerts
little influence on myogenic differentiation of C2C12 cells (sup-
plemental Fig. 8), suggesting that TLE3 amounts as well as the
right timing, or the existence of unknown TLE3 regulators, may
also be important for the regulation of myogenesis by TLE3.
It is also worth noting that a number of proteins have been
identified to act as myogenic antagonists by directly binding to
E proteins or MyoD family proteins and blocking their ability to
bind E box sequences and/or activate transcription at mus-
cle-specific promoters. Unlike TLE3, many of these inhibi-
tors are themselves HLH domain proteins and include Id,
Twist, MyoR, and Mist-1 (35). TLE3 interacts with MyoD
independently of its WD domain, which is the most highly
conserved portion of Groucho/TLE proteins. Instead, our
results suggest that both the Q and SP domains of TLE3 are
required to interact and repress MyoD (Fig. 5). It is interest-
ing to note that both the Q and SP domains of Gro4 (murine
TLE4) are also essential for its interaction with Pax5. How-
ever, the WD domain of Gro4 is still needed to repress the
transcriptional activity of Pax5 (36). In contrast, a shorter
Groucho/TLE family member lacking a WD domain, called
AES, is able to repress NF-B (37).
That said, our experiments cannot exclude the possibility
that other factors are also involved in the suppressive effect of
TLE3 on transactivation of MyoD. High levels of Id protein
repress MyoD activity indirectly (38), and another Groucho/
TLE family member, TLE4, up-regulates Id1 expression (39).
Because overexpression of TLE3 increased endogenous Id1
Figure 7. The suppressive mechanism of TLE3 on MyoD involves E protein. A, C3H10T1/2 cells were transfected with MG185-luc along with the indicated
plasmids, and luciferase activity was measured on day 1. B, cells were co-transfected with FLAG-tagged E12 along with empty vector (Mock), Myc-tagged MyoD,
or Myc-tagged TLE3. Whole-cell lysates were immunoprecipitated (IP) with anti-FLAG magnetic beads and immunoblotted (IB) with an anti-Myc or anti-FLAG
antibody. C, cells were co-transfected with FLAG-tagged MyoD and empty vector (Mock) or Myc-tagged E12 together with or without V5-tagged TLE3. The
whole-cell lysates were immunoprecipitated using FLAG-tagged magnetic agarose and immunoblotted with anti-Myc, anti-FLAG, or anti-V5 antibodies. The
data are expressed as mean  S.D. (n  3). *, p  0.05 versus mock-transfected cells (A). Similar results were obtained in three independent experiments (B and
C). D, a model for TLE3 regulation of MyoD transcriptional activity.
TLE3 represses MyoD transactivation
























levels in C3H10T1/2 cells (supplemental Fig. 9), it is possible
that TLE3 may regulate MyoD activity via direct and indirect
mechanisms. Additionally, because HES-1 inhibits the tran-
scriptional activity of MyoD (40), and Groucho/TLE family
members can interact with HES proteins, it is also possible
that TLE3 may cooperate with HES-1 during inhibition of
myogenesis. We find this possibility unlikely, however,
because the WD domain of TLE3 is required for interaction
with the WRPW domain of HES proteins (23) and, in our
hands, TLE3 mutants lacking the WD domain are capable of
suppressing MyoD activity to a similar degree as full-length
TLE3.
Understanding the mechanisms regulating how satellite cells
differentiate into myoblasts is a central question in muscle
pathophysiology (41, 42) because TLE3 is up-regulated in acti-
vated/proliferative satellite cells and suppresses myogenic dif-
ferentiation (Fig. 2). TLE3 is also expressed in myoblasts
derived from somites in the embryo (30), and the expression of
TLE3 in embryonic hind limb skeletal muscle is higher than in
adults (supplemental Fig. 10), suggesting that TLE3 may also
play an important role in skeletal muscle development in addi-
tion to satellite cell physiology. This raises the possibility that
TLE3 could be a potential target for stem cell– based therapies
for muscle-wasting diseases such as Duchenne muscular dys-
trophy and age-related sarcopenia. It is unclear at present, how-
ever, exactly how the expression of TLE3 is regulated. In addi-
tion, our study was mostly restricted to in vitro and ex vivo
models and used several different cell types. In vivo analyses
using conditional knock-out mice will be required to elucidate
the physiological function of TLE3.
Experimental procedures
Cell culture, skeletal muscle single-fiber culture, and
transfection
C2C12 cells and C3H10T1/2 cells were cultured and main-
tained as described previously (43). To induce myogenic differ-
entiation, C2C12 cells were grown to 90% confluence and then
cultivated for 2–5 days in DMEM containing 5% horse serum
(37). Single fibers of skeletal muscle and associated satellite cells
were prepared from mouse EDL muscles (44, 45). Detailed
experimental procedures can be found in the supplemental
information.
Animal experiments
The tibial anterior muscle of 10-week-old male C57BL/6
mice was injected with 50 l of 10 M cardiotoxin (Sigma-
Aldrich Chemicals, St. Louis, MO) using a 29-gauge 1/2 insulin
syringe. Muscles were removed 1, 3, 5, 7 10, and 14 days later
and immediately frozen in isopentane cooled in liquid nitrogen.
All studies were done in accordance with the guidelines of and
approved by the Experimental Animal Care and Use Commit-
tee of Kyushu Dental University.
Immunohistochemistry and immunocytochemistry analysis
Isolated single fibers, C2C12 cells, and C3H10T1/2 cells were
incubated with primary antibodies at 4 °C overnight following
blocking/permeabilization with phosphate-buffered saline
containing 0.3% Triton X-100 and 5% goat serum for 20 min at
room temperature. The following antibodies were used for
immunohistochemistry and immunocytochemistry: polyclonal
anti-TLE3 antibody (Proteintech, Chicago, IL), anti-TLE3
mouse monoclonal antibody (ab213596, Abcam, Cambridge,
UK), anti-Ki67 (ab92742, Abcam) anti-Myogenin mouse
monoclonal antibody (F5D, Santa Cruz Biotechnology, Santa
Cruz, CA), anti-MyoD mouse monoclonal antibody (5.8A,
Santa Cruz Biotechnology), anti-Pax7 mouse monoclonal anti-
body (sc-81648, Santa Cruz Biotechnology), anti-MHC mouse
monoclonal antibody (MF20, R&D Systems, Minneapolis,
MN), and CyclinD1 mouse monoclonal antibody (72-13G,
Santa Cruz Biotechnology). The target proteins were visualized
using an Alexa 488- or Alexa 594-conjugated secondary anti-
body (Invitrogen). A BZ-9000 (Keyence, Tokyo, Japan) micro-
scope was used for analysis. To visualize cell nuclei, cells were
mounted with Hard Set mounting medium with DAPI (Vector
Laboratories, Burlingame, CA). To visualize the cytoskeleton,
cells were stained with rhodamine phalloidin (Thermo Fisher
Scientific, Waltham, MA).
Plasmids
Plasmids encoding murine TLE3 have been described previ-
ously (28). Myf5 (accession no. NM_008656), MRF4 (accession
no. NM_008657), Myogenin (accession no. NM_0031189), E12
(accession no. NM_001164147), and Mef2 (accession no.
NM_001170537) were obtained by PCR amplification of mouse
cDNA using PrimeSTAR HS DNA polymerase (TaKaRa,
Ohtsu, Japan) and cloned into a FLAG-tagged or Myc-tagged
pcDEF3 expression vector (46). 0.8MCK-luc was con-
structed by subcloning a 1-kb fragment (1.8kb to 0.8 kb
relative to transcription start site) of the 5-flanking region
of the murine muscle creatine kinase gene (47) into the pGL4
promoter vector (pGL4.26). All constructs were confirmed
by sequencing. The FLAG-MyoD expression plasmid was
kindly provided by Dr. Takenobu Katagiri (Saitama Medical
University). The pGL3MG-185 luciferase plasmid (48) was
kindly provided by Dr. Kiyoshi Kawakami (Jichi Medical
University).
shRNA plasmid
Short hairpin RNA against murine TLE3 constructs
(shTLE3) was designed using the BLOCK-IT RNAi designer
tool (Invitrogen), and sense and antisense oligos were annealed
and cloned into pcDNA 6.2-GW/miR (28). The following
shRNA oligos were used: control shRNA, TGCTGAAATC-
GCTGATTTGTGTAGTCGTTTTGGCCACTGACTGAC-
GACTACACATCAGCGATTT; shRNA against TLE3, TGCT-
GTGCTGAGGCTGTCTTTCTCTT GTTTTGGCCACT GA-
CTGACAAGAGAAACAGCCTCAGCA. Only sense strands
are shown (28).
siRNA
siRNA against murine TLE3 (Stealth siRNA, MSS2385134,
Thermo Fisher Scientific) was transfected into primary satellite
cells or C2C12 cells according to the protocol of the manufac-
turer (49).
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The proliferation of plated satellite cells was assessed using
Cell Counting Kit 8 (Dojindo, Kumamoto, Japan) according to
the protocol of the manufacturer (50).
Chromatin immunoprecipitation assay
ChIP was performed with a ChIP assay kit (Cell Signaling
Technology, Beverly, MA) according to the instructions of the
manufacturer, using anti-FLAG antibody (Wako, Osaka, Japan)
and normal mouse IgG (MBL, Aichi, Japan). The purified DNA
was analyzed by PCR using primers that amplify sequences
within the Myogenin promoter region, which harbors MyoD
binding elements (48). The primer pairs for the MyoG pro-
moter were 5-GGA CCA TGG AGG AGA GAG TA-3 (for-
ward) and 5-CAT CAG GTC GGA AAA GGC TT-3 (reverse).
Luciferase assays
Luciferase assays were performed using MG185-luc, MCK
0.8-luc, or phRL-SV40 (Promega, Madison, WI) with the Dual-
Glo luciferase assay system (Promega) (51).
Reverse transcription and quantitative PCR (qPCR) analysis
Total RNA was isolated from murine skeletal muscle, murine
satellite cells, C2C12 cells, or C3H10T1/2 cells using TRIzol (Invit-
rogen) and then reverse-transcribed into cDNA using Superscript
IV (Invitrogen). The cDNA was amplified by PCR using specific
primers. Detailed primer sequences can be found in the supple-
mental information. SYBR Green-based quantitative real-time
PCR was performed in 96-well plates using Thunderbird
qPCR Mix (Toyobo, Osaka, Japan) with a 7300 real-time PCR
system (Applied Biosystems, Thermo Fisher Scientific). Values were
normalized to -actin using the 2-Ct method (52).
Immunoprecipitation and Western blot analysis
The following antibodies were used for immunoprecipita-
tion and Western blotting: anti-Myogenin mouse monoclonal
antibody (F5D, Santa Cruz Biotechnology), anti-MyoD poly-
clonal antibody (C-20, Santa Cruz Biotechnology), anti--actin
mouse monoclonal antibody (Sigma-Aldrich Chemicals),
anti-V5 mouse monoclonal antibody (Sigma-Aldrich Chemi-
cals), anti-Myosin heavy chain mouse monoclonal antibody
(MF20, R&D Systems), CyclinD1 mouse monoclonal antibody
(72-13G, Santa Cruz Biotechnology), CyclinA2 rabbit poly-
clonal antibody (GTX103042, GeneTex, Irvine, CA), and nor-
mal rabbit IgG (MLB). The target proteins were immunopre-
cipitated for 1 h at 4 °C using anti-DDDDK (FLAG) tag mAb
magnetic agarose (MBL) and anti-MyoD antibodies coupled to
protein G-Sepharose 4 Fast Flow (GE Healthcare UK Ltd.). The
target proteins were detected using a horseradish peroxidase-
conjugated anti-mouse or anti-rabbit IgG antibody (Cell Sig-
naling Technology). The immunoreactive proteins were visual-
ized using ECL (GE Healthcare UK Ltd.).
Statistical analysis
Comparisons were made using unpaired analysis of variance
with Tukey-Kramer post hoc test and Wilcoxon’s signed-rank
test. The results are shown as the mean  S.D. The statistical
significance is indicated as follows: *, p  0.05; **, p  0.01.
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Supplemental Figure 1. Myosin heavy chain (MHC) protein levels following TLE3 knockdown and overexpression	
Western blotting for MHC following shRNA knockdown of TLE3 in C2C12 cells shows increased MHC protein levels (A). 
Overexpression of TLE3 in C3H10T1/2 cells decreased the protein levels of MyoD-induced MHC expression (B). Data are 




























































Supplemental Figure 2   
Supplemental Figure 2. C3H10T1/2 cells express low levels of TLE3 and MyoD	
(A-B) qPCR analysis of MyoD (A) and TLE3 (B) mRNA levels in C2C12 and C3H10T1/2 cells. The data are expressed as the 
mean ± SD (n = 3). **, p < 0.01 relative to C2C12. Western blotting analysis of MyoD and TLE3 protein levels in C2C12 cells 





























































































































































Supplemental Figure 3. TLE3 represses the transcriptional activity of Myf5, Myogenin and MRF4 	
(A-C) C3H10T1/2 cells were transfected with TLE3 and MG185-luciferase reporter along with Myf5 (A), Myogenin (B) or MRF4 (C) 
Luciferase activity was determined on day 1. (D-F) C3H10T1/2 cells were transfected with TLE3 and MCK0.8-luciferase reporter along with 
Myf5 (D), Myogenin (E) or MRF4 (F). Luciferase activity was determined on day 1. The data are expressed as the mean ± SD (n = 3). **, p < 
0.01 versus mock-transfected cells (A-F).	
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Supplemental Figure 4. The WD domain deletion mutant of TLE3 (1-461) fails to repress Runx2 transcriptional activity	
C3H10T1/2 cells were transfected with OSE2-luc reporter plasmid along with TLE3 1-782 (Full length) or TLE3 1-461 (WD 
deletion mutant) together with or without Runx2. Full length TLE3 repressed OSE2-luc activity induced by Runx2 whereas 
TLE3 WD deletion mutant did not. Luciferase activity was performed on day 1. The data are expressed as the mean ± SD (n = 



















Supplemental Figure 5. Overexpression of E12 slightly, but significantly, increases MG185-luc activities	
C3H10T1/2 cells were co-transfected with 0, 50, 100, or 200 ng of E12 plasmid along with MG185-luc reporter plasmid after which 
luciferase activity was measured 24 h after transfection. The data are expressed as the mean ± SD (n = 3). **, p < 0.01 , *, p < 0.05 versus 
0 ng E12 control. 	
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Supplemental Figure 6. TLE3 does not interfere with the interaction between Mef2 and MyoD	
C3H10T1/2 cells were co-transfected with FLAG-tagged MyoD and Myc-tagged Mef2 along with or without V5-tagged TLE3. Whole-cell 
lysates were immunoprecipitated (IP) using FLAG-tagged magnetic beads and immunoblotted (IB) with anti-Myc, anti-FLAG, or anti-V5 
antibodies. Similar results were obtained in three independent experiments (A). C3H10T1/2 cells were transfected MG185-luciferase 
plasmid together with the indicated amounts of MyoD, TLE3 or Mef2 plasmids. Luciferase activity, measured 24 h after transfection, 
showed that Mef2 did not rescue the suppressive effect of TLE3 on the transcriptional activity of MyoD. The data are expressed as the mean 










Supplemental Figure 6   
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Supplemental Figure 7   
A
B
Supplemental  Figure 7. TLE3 is expressed in Myogenin positive satellite cells 
Immunocytochemistry on satellite cells plated on matrigel showed that TLE3 was expressed in myogenin positive proliferating satellite cells 
maintained in growth medium (GM) for 7 days after isolation. Scale bar represents 40 µm. Similar results were obtained in three independent 










































Supplemental Figure 8   
Supplemental Figure 8. Overexpression of TLE3 exerts little influence on myogenic differentiation of C2C12 cells 	
(A-C) C2C12 cells were transfected with or without Myc-tagged TLE3. Whole-cell lysates were immunoblotted with an anti-Myc, anti-
Myogenin, anti-MHC, or anti-β-actin antibodies on day 3 (A). Immunohistochemical analysis was performed using anti-MHC antibody 
on day 3. Scale bar represents 100 µm (B). The number of MHC-positive fibers were counted on day 3. The data are expressed as the 
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 0.2	 0.4	 0.8	
Supplemental Figure 9. Overexpression of TLE3 induced mRNA levels of Id1 in C3H10T1/2 cells 	
C3H10T1/2 cells were transfected with empty vector, or TLE3 expression vector and mRNA levels of Id1 were determined by 
qPCR on day 2. The data are expressed as the mean ± SD (n = 3). ** p < 0.01, * p < 0.05  versus mock-transfected cells.	
	






















































































B C D E
Supplemental Figure 10. TLE3 expression levels in embryonic skeletal muscle are higher than in adult skeletal muscle	
(A-E) Total RNA was isolated from the skeletal muscle of mice at 10-weeks old or at embryonic day 16.5. qPCR analysis was performed 
using specific primers for TLE3 (A), MyoD (B), Myf5 (C), Myogenin (D), or MRF4 (E). The data are expressed as the mean ± SD (n = 3). 
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